Industry deeply disappointed as FDA reportedly puts cell and gene therapy chief on leave
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency.
The Alliance for Regenerative Medicine has voiced deep disappointment about reports that the FDA has put the director of its cell and gene therapy office on administrative leave and escorted her out of the agency.
